-0.010 (-0.55%)
Range 1.710 - 1.860   (8.77%)
Open 1.780
Previous Close 1.820
Buy Price 1.880
Buy Volume 31
Sell Price 1.890
Sell Volume 12
Volume 839,111
Value -
Measurement Type Value
EPS (USD) -0.404
Trailing EPS (USD) -0.471
NAV (USD) 0.771
Cash In Hand (USD) 0.245
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 2.346
Price / Cash In Hand 7.4
Issued & Paid-up Shares 48,187,500
Treasury Shares -
Market Cap (M) 87.219
Par Value (USD) n.a.
Beta - 75 Days 1.935
R-Squared - 75 Days(%) 14.33
Beta - 500 Days 0.78
R-Squared - 500 Days(%) 11.19
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 27 Feb 2021 05:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 31 Mar 2021
View All Events


Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its clinical pipeline is based on two platform technologies that leverage the body�s natural physiologic and genetic regulatory elements. As of June 6, 2014, it has developed two programs based on these platforms an oncology program and an anti-inflammatory program. Its lead product candidate from its oncology program, VB-111, is a gene-based biologic that is initially developing for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. The Company has also received orphan drug designation in both the United States and Europe. The Company�s oncology program is based on its Vascular Targeting System (VTS), platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Loading Chart...